Holen Sie sich die Stockscreener-App
6.28
0.16%
0.01
Eyepoint Pharmaceuticals Inc Aktie (EYPT) Neueste Nachrichten
230,745 Shares in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Acquired by abrdn plc - MarketBeat
Brokerages Set EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Target Price at $26.63 - MarketBeat
EyePoint Pharmaceuticals (NASDAQ:EYPT) Given "Buy" Rating at Chardan Capital - MarketBeat
EyePoint Pharmaceuticals (NASDAQ:EYPT) Reaches New 52-Week LowTime to Sell? - MarketBeat
EyePoint Pharmaceuticals (NASDAQ:EYPT) Earns Buy Rating from Chardan Capital - Armenian Reporter
EyePoint's decline following positive data makes no sense, says analyst - MSN
EyePoint Pharmaceuticals Inc [EYPT] Shares Fall Approximately -76.18% Over the Year - Knox Daily
EyePoint Pharmaceuticals (NASDAQ:EYPT) Receives Buy Rating from Chardan Capital - Armenian Reporter
Investors unsure on EyePoint’s Duravyu blockbuster claim - The Pharma Letter
A significant driver of top-line growth: EyePoint Pharmaceuticals Inc (EYPT) - SETE News
There Is A Lot Of Upside Potential For EyePoint Pharmaceuticals Inc(NASDAQ: EYPT) - Stocks Register
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Given Consensus Recommendation of “Buy” by Analysts - ETF Daily News
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Given Average Recommendation of “Buy” by Analysts - Defense World
EyePoint stock jumps 10% on Duravyu study results - MSN
(EYPT) Investment Analysis - Stock Traders Daily
Analyzing the Impact of Earnings Reports on EyePoint Pharmaceuticals Inc Inc. (EYPT) Price Performance - The InvestChronicle
TD Cowen maintains EyePoint stock Buy rating, $20 target - Investing.com India
Short Interest in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Rises By 9.9% - MarketBeat
EyePoint Pharmaceuticals : Investor Presentation February 2025 - Marketscreener.com
EyePoint stock jumps 10% on Duravyu study results (EYPT:NASDAQ) - Seeking Alpha
EyePoint's Phase 2 Trial of Duravyu to Treat Diabetic Macular Edema Meets Endpoints; Shares Still Slump Pre-Bell - Marketscreener.com
Collegium Appoints Nancy S. Lurker to its Board of Directors - citybiz
EyePoint’s decline following positive data makes no sense, says analyst By Investing.com - Investing.com Nigeria
EyePoint's decline following positive data makes no sense, says analyst By Investing.com - Investing.com South Africa
Pharma Veteran Nancy Lurker Joins Collegium Board: Ex-Novartis CMO Brings M&A Expertise - StockTitan
EyePoint Announces Positive Six-Month Results for the Phase 2 VERONA Clinical Trial of DURAVYU™ for Diabetic Macular Edema Meeting Primary and Secondary Endpoints - The Manila Times
EyePoint Pharmaceuticals stock sinks following clinical trial results By Investing.com - Investing.com South Africa
Should investors be concerned about EyePoint Pharmaceuticals Inc (EYPT)? - US Post News
EyePoint Pharmaceuticals stock sinks following clinical trial results - Investing.com
Clinical Trial Success: EyePoint's DME Drug Reduces Treatment Burden by Two-Thirds - StockTitan
Analyzing EyePoint Pharmaceuticals Inc (EYPT) After Recent Trading Activity - Knox Daily
Financial Health Report: EyePoint Pharmaceuticals Inc (EYPT)’s Ratios Tell a Tale - The Dwinnex
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Short Interest Update - Defense World
EyePoint: A Risky 'Buy' Ahead Of Key Readout For Long-Acting Eylea Rival (NASDAQ:EYPT) - Seeking Alpha
EyePoint Pharmaceuticals' CEO Jay S. Duker to Speak at Guggenheim SMID Cap Biotech Conference on February 6, 2025 - Nasdaq
EyePoint to Present at Guggenheim SMID Cap Biotech Conference - The Manila Times
Inside EyePoint's Strategy: CEO Set to Reveal Latest Developments in Retinal Disease Treatment - StockTitan
Franklin Resources Inc. Expands Portfolio with EyePoint Pharmace - GuruFocus.com
Long Term Trading Analysis for (EYPT) - Stock Traders Daily
Strong week for EyePoint Pharmaceuticals (NASDAQ:EYPT) shareholders doesn't alleviate pain of one-year loss - Yahoo Finance
Brokers Offer Predictions for EYPT FY2025 Earnings - Defense World
EyePoint Pharmaceuticals (NASDAQ:EYPT) Trading 6.1% HigherShould You Buy? - MarketBeat
Research Analysts Issue Forecasts for EYPT FY2025 Earnings - MarketBeat
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Short Interest Up 9.9% in December - MarketBeat
JPMorgan Chase & Co. Purchases 342,516 Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) - MarketBeat
JPMorgan Chase & Co. Raises Stock Position in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) - Defense World
EyePoint Pharmaceuticals Inc (NASDAQ:EYPT) Has Recovered 7.75% So Far, But Another -314.3% Loss Is Possible. - Marketing Sentinel
EyePoint Pharmaceuticals (NASDAQ:EYPT) Trading Up 3.4%Here's What Happened - MarketBeat
Further weakness as EyePoint Pharmaceuticals (NASDAQ:EYPT) drops 20% this week, taking one-year losses to 68% - Simply Wall St
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
EyePoint Pharmaceuticals Awards Stock Options to New Employees in Retention Move - StockTitan
(EYPT) Trading Signals - Stock Traders Daily
2.27%
5.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):